Security key
746964105
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 8,065,328
- Total 13F value
- $144,178,979
- Share change
- +631,360
- SEC-reported price per share
- $17.95
- Number of holders
- 54
- Value change
- +$11,388,677
- Number of buys
- 34
- Number of sells
- 10
- Shares outstanding
- 29,802,568
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
54
Top holders
10
QTTB full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Q32 Bio Inc. SEC filings
Q32 Bio Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 746964105
Recent filing periods:
Ownership snapshot
Top reported holders of QTTB - Q32 Bio Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Atlas Venture Fund X, L.P.
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
0/15
Latest evidence
31 Mar 2024
3/4/5
13F
Highest disclosed value: $38,390,898
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC has the largest disclosed position value at $38.39M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Disclosed position value
Top 5
Atlas Venture Fund X, L.P.
$1.19M
ORBIMED ADVISORS LLC
$38.39M
Atlas Venture Life Science Adviso...
$35.65M
Carlyle Group Inc.
$18.07M
Vivo Capital, LLC
$6.31M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Atlas Venture Fund X, L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,194,801
2,092,106 shares
|
— | 25 Mar 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$38,390,898
2,252,987 shares
|
— | 31 Mar 2024 |
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
—
denominator unverified
|
$35,649,486
2,092,106 shares
|
— | 31 Mar 2024 |
| Carlyle Group Inc. |
13F
Company
|
—
denominator unverified
|
$18,073,925
1,102,741 shares
|
— | 31 Mar 2024 |
| Vivo Capital, LLC |
13F
Company
|
—
denominator unverified
|
$6,305,959
370,068 shares
|
— | 31 Mar 2024 |
| ARCH Venture Management, LLC |
13F
Company
|
—
denominator unverified
|
$5,461,013
320,482 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
54
Shares
8,065,328
Rows available
54
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2026 Across Filers
Q1 2026 holders
53
Q2 2024 holders
54
Holder diff
1
| Investor | Q1 2026 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend